<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 361 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page360.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=361">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 361 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 361</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=361"><img src="../thumb/361.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>324 / 2020-04                                                 Cytostatics / Immunological - 23 / 24 / 24.1
   (S4) POWD.FOR SOL.FOR INJ, 49/26/0891. 1 mg/ml reconstit.  XTANDI, Astellas &  incr. sweat., dermatit., photosens., tox.epiderm. necrolys. (Lyell’s
   722781-001: 3,5 mg,1x10 ml vial, R5 237,92  Enzalutamide   syndr.), Stev.Johns.syndr., arthralg., musc.cramps, limb/back pain,
   For further details refer to manufact.prod.lit.  Indications: Metastat.castrat.-resist.prostate Ca  joint disords, hirsut., hyperglyc.condits., diabet.mellit., hypo/hyper-
   VATIVIO 100, Novartis [P/S]  (S4) CAPS, 48/26/0404. 40 mg  kalaem., hypomagnesaem., hyper/ hypophosphataem., hypocal-
                                                              caem., hyponatraem., fluid overload, hyperuricaem., decr.appetit./
                                721978-001: 112, R30 061,00
   Imatinib                     Dosage: 160 mg (4 caps) as sngl.dly oral dos.  anorex., metabol.acidos., hyperlipidaem., hypercholesterolaem.,
   Indications: Adult & paed.pts: New.diagn Philadelph.chromosome   Contraindications: Hypersens., women  hypertriglyceridaem., other electrol. abnormal., dehydrat., hypo-
   positive chron.myeloid leukaem (CML)., CML in blast crisis/accelerat./   Side effects: Asthen., fatig., hot flush., headache, hypertens., falls,   proteinaem., hypoglycaem., incr.suscept.to infects., prim.graft
   chron. phase aft.interferon-alpha ther.fail.  non-patholog.fract., cognit. disord., neutropen., seiz., anx., vis.hallu-
   Adult pts: New.diagn.Philadelph.chromosome positive        dysfunct., benign & malign.neoplasms, skin. malign., hypertens.,
   ac.lymphoblast.leukaem. (Ph+ALL) intergrat. with chemother., re-  cinat., attent. disturbs., restless leg syndr., gynaecomast., dry skin,   haemorrh., thrombembol/ ischaem. events, periph.vasc.disords.,
   laps./refract.Ph+ ALL as monther., myelodysplast./myeloproliferat.  prurit., myalg., musc.spasm, musc. weakn., back pain, post.revers.  vasc. hypotens. disords., infarct., deep limb ven. thrombos., shock,
   dis. (MDS/MPD) assoc.with platelet-deriv.growth fact. recept.(PDGFR)   encephalopathy syndr.  asthen.condits., febril.disords., oed., pain/discomf., incr.bld.alkalin.
   gene re-arrangem., system. mastocytos. (SM) without the D816V c-Kit   Warnings and special precautions: Seiz.hist./ predispos.fact.,   phosphat., incr/ decr.weight, disturb.body temp.percept., multi-org.
   mutat.& eosinophil., hypereosinophil.syndr.(HES) &/chron. eosinophil.  concom.meds.low.seiz.threshold, not stud.in sev.hepat.impairm.,   fail., influenza-like illn., temp.intol., chest press. sensat., jitter/ab-
   leukaem.(CEL) with FIP1L1-PDGFR alpha rearrangem., unresect.&/or   sorbitol intol., determ. S/E profile bef.driv./operat.mach., strong CY-  norm.feel., incr.bld.lactat. dehydrogenas., thirst, fall, tight chest,
   metastat.malign. gastrointest.stromal tumours (GIST), adjuv.treatm.   P2C8 inhibit./induc., meds.with narr.therapeut. range which are sub-  decr. mobilit., ulcer, incr.fat tiss., allerg./anaphylact. reacts., hepat.
   follow.resect.of Kit-posit.GIST, unresect./recurr.&/ metastat.der-  strates of CYP3A4/CYP2C9/ CYP2C19/UGT1A1/ P-gp/BCRP & MRP2   enzym/funct.abnorm., cholestas., jaund., hepatocell.damag., hep-
   matofibrosarcoma protuberans (DFSP)  poss. requir. dos.adjustm.to maint.therapeut.plasma conc., condom   atit., cholangit., hepatit. art.thrombos., veno-occlus.liv.dis., hepat.
   (S4) CAPS, 36/34/0139        use and another form of birth control recomm.dur.& for 3 mnths aft.  fail., bile duct stenos., dysmenorrh., uter.bleed., insomn., anx., con-
   718477-001: 100 mg, 120, R13 150,00  treatm., horm.lev.changes expect poss.affect.foet. developm., sev.  fus., disorientat., depress./ depress.mood, mood disords./disturbs.,
   For further details refer to manufacturers prod. lit.  ren.impairm./end-stage ren.dis.  nightmares, hallucinat., ment./psych.disords., BK virus assoc. ne-
                                                              phropathy, JC virus assoc.progress. multifoc. leukoencephalopathy
                                Drug interactions: Strong CYP2C8 inhibit incr. AUC while Cmax
   6VELCADE, Janssen Pharmaceutica [P/S]  decr., sensit.CYP substrates decr their AUC, poss.incr.in plasma conc.  (PML), EBV-assoc. lymphoproliferat.disords., post.revers. encepha-
   Bortezomib                   of BCRP & MRP2 substrates.    lopathy syndr. (PRES)., vis./neurologic. disturbs.
   Indications: Prim.treatm.of multip.myeloma in combinat.with mel-  See also MDR page 219.  Special precautions: Cross.the placenta, contracept. other than
   phalan & prednisone, monother. for multiple myeloma where at   OC’s, MRI should be perform. if pts present.with PRES, adeq.BP
   least one prior ther. receiv.& dis.progress., relaps.or refract.mantle   YERVOY, Equity [P/S] &  contr. & immed. discont.of system.tracrolimus if PRES diagn., vis./
   cell lymphoma treatm.for pts.who have receiv.at least 1 prior line of   Ipilimumab  neurologic.disturbs., diagnos./suspect. long QT syndr., pts.who have
   ther.one of which incl.an anthracycline (or mitoxantrone) &/ rituximab   Indications: Prev.treat.unresectable/metast. melanoma  prev.receiv. ciclosporin, monit.bld.conc.dur.diarrh.epis., vaccinat. less
   as part of chemother.regim.  (S4) SOL.FOR.INFUS, 47/30.1/0522. 5 mg/ml  effect., avoid live attent.vacc., meds. with nephrotox. effs., high K   +
   (S4) POWD.FOR SOL.FOR IV INJ, 43/26/0427. 1 mg/ml reconstit.  720814-001: 1x10 ml, R50 667,29  intake/K spar. diuret., avoid mix.with other drugs., teratogen.at dos.
                                                                  +
   723386-001: 1 mg, 1x5 ml vial, R2 132,10  720815-001: 1x40 ml, R202 669,08  that also demonstr.maternal toxic., excret.in breast milk, other immu-
   (S4) POWD.FOR SOL.FOR IV & SC INJ, A40/26/0005. 1 mg/  For further details refer to professional info.  nosuppress.ther., incr. suscept. to vir./bact./fung.& protozoal infects.,
   ml reconstit.(IV use)        See also MDR page 295.        imp. liv./kidn.funct., prolong.releas.formulat.not interchang. with
   2,5 mg/ml reconstit.(SC use)                               immediat.releas.formulat.of tacrolim., UV/sun expos., for details
   706787-001: 3,5 mg, 1x10 ml vial, R7 310,74  ZAVEDOS, Pfizer [P/S]  concern.pt. monit. by special physic.refer.to prod.lit.
   For further details refer to professional info.  Idarubicin HCl.  Drug interactions: Vis./neurological disturbs. effs. enhanc.with
                                Indications: Ac.non-lymphocyt.leukaem., incl. ac.myeloblast.
   VESANOID, Pharmaco [P/S]     leukaem.in adults as front-line therapy/remiss.induct.in relaps./  concom.alcoh., incr./decr.plasma lev. with methylprednisolone,
   All-trans retinoic acid.     refract.pts.                  incr.whole bld./ plasma lev.with imidazole antimycot./macrolide
   Indications: Induct.of remiss.in ac.promyelocyt. leukaem.(APL:FAB   (S4) INJ, [P/S] Y/26/16, 17.  antibiot./nifedipine/nicardipine/HIV protease inhibits./ danazol/
   class.AML-M3) for prev. untreat. pts., those who relapse aft./re-  788651-005: 5 mg, sngl.vials, R1 088,63  omeprazole/ethinylestradiol & Ca antagon., enhanc.nephrotoxic.
   fract.to std. chemother.     788678-019: 10 mg, sngl.vials, R2 114,47  with amphotericin-B/ibuprofen, decr.bld.lev.with rifampicin/ phe-
   (S5) CAPS. 29/26/0087.       For further details refer to manufact.prod.lit.  nytoin/phenobarbital & St.John’s Wort, bld.lev.of phenytoin.incr.,
   820008-001: 10 mg, 100, R4 155,95                          decr.clear.& incr. half-life of pentobarbital/antipyrine, ciclosporin
   For further details refer to manufact.prod.lit.  ZELBORAF, Roche   half life incr., inhib.eff.on cytochrome P-450 3A4, bromocriptine,
   VIDAZA, Key Oncologics       Vemurafenib                   cortisone, dapsone, ergotamine, ethinylestradiol, gestodene, itra-
                                                              conazole, josamycin, lignocaine, mephenytoin, miconazole, mida-
   Azacitidine                  Indications: Monother.treatm.of adult pts.with BRAF V600E   zolam, nicardipine, nifedipine, norethindrone, quinidine, tamoxifen,
   Indications: Myelodysplastic.syndr.incl.refract. anaem. /refract.  mutat.-positiv.unresectable/ metastat. melanoma.  triacetyloleandromycin, verapamil inhib.metabol., naringenine( flave-
   anaem.with ring.sideroblasts (if accomp.by neutropen./thrombo-  (S4) TABS, 47/32.16/0247.  noid.in grapefruit juice) inhib.cytochrome P-450 3A4 syst., poss. decr.
   cytopen./req. transfus.) /exess blasts/exess blasts in transformat.,   720736-001: 240 mg, 56, R24 077,98
   chron.myelomonocyt.leukaem.  For furth.details refer to prof. info.  lev.with barbits., phenytoin, rifampicin, carbamazepine, metamizole
                                                              & isoniazid, induc.of cytochrome P-450 3A4 syst., inhib.cortisone
   (S4) INJ, A40/26/0521. 25 mg/ml
   712413-001: 1x100 mg/4ml vial, R5 648,42                   & testosterone metabol., decr.effic.OC’s, other plasma prot bind.
   For further details refer to manufact.prod.lit.  24  IMMUNOLOGICAL  meds.e.g. oral anticoags./ antidiabets., enhanc.neurotox.of ganci-
                                                              clovir/ aciclovir, meal of mod.fat cont.reduc.bioavail./ absorpt. sig-
   VINBLASTINE TEVA, (Cipla Medpro) Teva [P/S]                nific., poss.incr.risk of over-immunosuppress. if given tog.with other
   Vinblastine sulphate.                                      potent immunosuppress.meds.
   Indications: Treatm.of malign.non-Hodgkin’s lymphomas, Hodgkin’s   24.1  Immunosuppressants  See also MDR page 201.
   dis., Ca of testes, chorio & breast Ca.
   (S4) INJ. 45/26/0373. 1 mg/ml.  ADVAGRAF (MDR Listing)     AFINITOR, Novartis [P/S]
   722790001: 1x10 ml vial, R277,25  PROGRAF (MDR Listing)    Everolimus
   For further details refer to manufact.prod.lit.  RAPAMUNE (MDR Listing)  Indications: Palliat.treatm.of adv.ren.cell Ca.in pts.who fail.prior
                                                              treatm.with VEGFTR-TKI ther., in combinat.with exemestane for
   VOTRIENT, Novartis [P/S]     SIMPONI (MDR Listing)         palliat.treatm.of postmenopaus. women with oestrog.recept.posi-
                                STELARA (MDR Listing)
   Pazopanib                                                  tiv. HER2/neu neg.adv.breast Ca.with recurr./progress.aft.prior non-
   Indications: Advanc.&/metastat.ren.cell Ca  TYSABRI (MDR Listing)  steroid.aromatase inhibit.treatm., advanc. neuroendocr.tumours of
   (S4) TABS, 44/26/0348, 0349  ADVAGRAF, Astellas [P/S] &    pancreat.origin, tuberous scleros complex (TSC) with ren.angiomy-
   720861-001: 200 mg, 30, R8 025,72  Tacrolimus              olipoma not req.immed.surg.
   720862-001: 400 mg, 30, R16 051,43  Indications: Prophylax.of transpl.reject.in adult kidn./liv.allograft   (S4) TABS, 46/34/0696; 43/34/1010, 1133
   For further details refer to manuf.product lit.  recip., treatm.of allograft reject. resist.to treatm.with other immu-  716750-001, 5 mg, 30, R17 068,68
   XALKORI, Pfizer [P/S] &      nosuppress.meds. in adults    716749-001, 10 mg, 30, R34 137,36
   Crizotinib                   (S4) PROLONG.REL.CAPS, [P/S] A42/34/0786, 0787, 0788  Dosage: Admin.only by experienc.physic. Admin. same time each
   Indications: Anaplastic lymphoma kinase (ALK)-positive advanc.   717628-001, 0,5 mg, 30’s, R663,23  day consist.with/without food. Swallow whole, do not chew/crush.
   non-small cell lung Ca (NSCLC).  717629-001, 1 mg, 30’s, R1 208,54  Maybe dissolv. in water for those unable to swallow tabs. See lit
   (S4) CAPS, 47/26/0568, 0569  717630-001, 5 mg, 30’s, R5 880,53  for dos adjust.& managem.recommendat. for advers.drug reacts.
   722115-001: 200 mg, 60, R67 259,70  Dosage: Refer to manufact.lit.for furth. details.  Advanc.neuroendocr.tumours of pancreat. origin/advanc.ren.
   722620-001: 250 mg, 60, R67 259,70  Contraindications: Pregn.& lactat., macrolide hypersens.  cell Ca./advanc.breast Ca & TSC with ren.angiomyolipoma:
   For further details refer to manufact.prod.lit.  Side effects: Ischaem.coron.art.disord., tachycard., ventric.dys-  Adults: 10 mg once dly. If dos.reduct.requir.reduc.to 5 mg once dly.
   See also MDR page 667.       rhythm.& card.arrest, HF, cardiomyopath., ventric.hypertrop., su-  Concomit.mod.CYP3A4/PgP inhibit: Reduc.dos. to 5 mg once dly.
   XELODA, Roche [P/S]          praventric. dysrhythm., palpit., abnorm.ECG invest/heart rate &   Further dos.reduct.to 5 mg every other day or 2,5 mg dly.may be req.to
                                puls. invest., pericard.effus., abnorm echocardiogr., bld.dyscras.
                                                              manag. advers. reacts. Consid.washout per.of 2-3 days if mod. inhib.
   Capecitabine                 incl.abnorm.red blood cell analys., thrombot.thrombocytopen.pur-  discont.bef.incr.Afinitor dos.
   Indications: Loc.advanc./metastat.breast Ca: Combinat. ther.  pura & hypoprothrombinaem., trem, headache, seiz., disturb. in   Concom.strong CYP3A4 induc: Consid.doubl. dly.dos.using 5 mg
   with docetaxel aft.fail of cytotox. ther.incl.of anthracycline. Mono-  consciousn., paraesthes./dysaesthes., periph. neuropathy, dizzin.,   increm.however there is no clinic. data with this dos.adjustm. If
   ther.aft.fail.of taxanes and an anthracycline contain.regim.where   impair.writing, nerv. syst. disords., coma, CNS haemorrh.& CVA,   strong induc. discont.consid.washout per.of at least 3-5 days bef.
   anthracycline ther.not further indicat.  paralys./ paresis, encephalopathy, speech & lang. abnormalit.,   Afinitor dos.resum.at prior dos.
   Colorect.Ca: Adjuv.aft.surg.in Dukes C colon Ca., metastat.colo-  amnes., hyperton., myasthen, blurr. vis., photophob., eye disords.,   See lit for concom.mod.CYP3A4 or PgP inhibit./ strong CYP3A4 induc.
   rect.adenocarcinoma (benef.relates to time to progress.which over-  cataract, blindn., tinnit., hypoacus., neurosens.deafn., imp.hear.,   Contraindications: Rapamyc.derivat.hypersens., live vaccine use,
   all surviv.not influenc.)    dyspn., parenchym.lung disords., pleur.effus., pharyngit., cough,   pregn. & lactat.
   Gastric Ca: 1 st  line treatm.of advanc.gastric adenocarcinoma in   nas.congest.& inflammat., resp. fail., resp.tract disords, asthma,   Side effects: Infects., bld dyscras., hypersens., decr.appetite, hyper-
   combinat.with other anti-chemotherapeut.regim. (benef.relates to   ac.resp.distress syndr., GI disords incl.GI ulcerat.& perforat., sto-  glycaem. hypercholesterolaem. hypertriglyceridaem., hyperlipidaem.,
   time to progress.which overall surviv.not influenc.)  matit., ascit., paralyt.ileus, peritonit., ac.& chron. pancreatit., incr.  hypophosphataem., diab.mellit., hypokalaem., dehydrat., insomn.,
   (S4) TABS, 33/26/0198, 0199  bld amylas., GERD, imp. gastr.empt., subil., pancreat.pseudocyst,   anx., somnol., dysgues., headache, ageus., CCF, hypertens., haem-
   870072-005: 150 mg, 60, R581,93  ren. impairm./fail., oligur., ren.tubul.necros., tox. nephropathy,   orrh., DVT, pneumonit., epistax., cough, dyspn., haemoptys., pulm.
   870080-008: 500 mg 120, R3 977,46  urin.abnorm., bladd.& urethr.sympts., anuria, haemolyt.uraem.  embol., ac.resp.distress syndr., stomatit., diarrh., N&V, dry mouth,
   For further details refer to manufact.prod.lit.  syndr., nephropathy, haemorrh. cystit., prurit., rash, alopec., acne,   abdom.-/oral pain, mouth ulc., oral mucosit., dyspeps., dysphag.,</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page360.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page356.html">356</a>&nbsp;&nbsp;&nbsp;<a href="page357.html">357</a>&nbsp;&nbsp;&nbsp;<a href="page358.html">358</a>&nbsp;&nbsp;&nbsp;<a href="page359.html">359</a>&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>
             </td>
             <td width="35%"><a href="page362.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page362.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
